Tag: Cancer: Colon

In study, patients with CRC as the only malignancy had more frequent liver and lung metastases and received systemic adjuvant treatments more often

Multitarget stool DNA testing was cost-effective relative to no screening, but CT colonography is cost-saving

In an average-risk colorectal cancer screening population, a blood-based circulating tumor DNA test is feasible

Only risk of any adenoma differed between the groups

Improved survival seen with structured program in patients with resected colon cancer who have completed adjuvant chemo

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations

Cost per additional cases of CRC, advanced neoplasia would still be manyfold higher if costs per test were lowered

Countries with higher colorectal cancer incidence rates have higher mutation loads in signatures caused by bacteria-produced mutagen colibactin

Approximate doubling of up-to-date status seen among Asian, Black, Hispanic, White patients, with corresponding decrease in CRC incidence, deaths

Increase seen across age groups, while incidence of colorectal adenocarcinoma increased most in those aged 15 to 34 years